Remove Compound Screening Remove Drugs Remove Gene Editing Remove Pharma Companies
article thumbnail

What to expect from drug discovery and development in 2023

Drug Discovery World

According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% The modernisation of R&D models could be key to reducing spend on new drugs, a point that Deloitte makes about the need to transform the clinical trials process. the industry experienced in 2021.